Tiziana Life Sciences Ltd
TLSA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for TLSA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TLSA
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company developing foralumab, an anti-IL6R monoclonal antibody, primarily via intranasal administration for neurodegenerative and autoimmune indications, with no approved products and recurring operating losses.
Key risk: Going concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2024.
Tracking 5 clinical trials · 2 catalysts for Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company developing foralumab, an anti-IL6R monoclonal antibody, primarily via intranasal administration for neurodegenerative and autoimmune indications, with no approved products and recurring operating losses.
- Lead candidate is foralumab (TZLS-501), an anti-IL6R monoclonal antibody being developed for secondary progressive multiple sclerosis, Type 1 Diabetes, and Long COVID [sec · filed 2026-05-01].
- Cash and cash equivalents were $4.0M as of December 31, 2025 [sec · filed 2026-05-01]; net loss was $18.4M for the year ended December 31, 2025 [sec · filed 2026-05-01].
- The company has incurred operating losses since inception and expects to continue incurring significant expenses [sec · filed 2026-05-01].
- Independent auditors have expressed substantial doubt about the company's ability to continue as a going concern [sec · filed 2026-05-01].
- Proprietary technology focuses on alternative routes of administration (oral and nasal) to reduce burden compared to intravenous delivery [sec · filed 2026-05-01].
What works
- Proprietary technology enables oral and nasal delivery of antibodies, potentially reducing time and cost burdens associated with intravenous administration [sec · filed 2026-05-01].
- Strong network of key opinion leaders, including Dr. Napoleone Ferrara, Dr. Arun Sanyal, Dr. Kevan Herold, and Dr. Howard Weiner, supports clinical development [sec · filed 2026-05-01].
- Pipeline targets large neuroinflammatory and neurodegenerative markets with significant commercial potential [sec · filed 2026-05-01].
What to weigh
- The company has not yet demonstrated ability to successfully complete Phase 3 or pivotal clinical trials, obtain regulatory approvals, or commercialize any product candidate [sec · filed 2026-05-01].
- Cash and cash equivalents of $4.0M as of December 31, 2025 may be insufficient to fund operations for the next 12 months, with a going concern qualification from auditors [sec · filed 2026-05-01].
- Net losses have been sustained since inception, with a net loss of $18.4M for the year ended December 31, 2025 [sec · filed 2026-05-01].
- Uncertainty around the scope, timing, and costs of preclinical and clinical development, including patient enrollment and regulatory approval [sec · filed 2026-05-01].
From the filings
Quoted directly from source documents.
Cash position as of Dec 31, 2025
“As of December 31, 2025, we had cash and cash equivalents of $4.0m.”
SEC filings · May 1, 2026
Net loss for 2025
“Our net loss after taxation was $18.4m for the year ended December 31, 2025”
SEC filings · May 1, 2026
Lead product candidate
“the development of Foralumab, an anti-IL6R monoclonal antibody (TZLS-501)”
SEC filings · May 1, 2026
Catalyst timeline
- 2026-09-30 · Phase2_Topline · intranasal foralumab — Phase 2 Readout: intranasal foralumab — Topline data from Phase 2 trial of intranasal foralumab expected; results will inform efficacy and safety for further development.
- 2026-12-31 · Phase2_Topline · intranasal foralumab — Phase 2 Readout: intranasal foralumab — Additional Phase 2 readout for intranasal foralumab; outcome may impact regulatory and financing strategy.
Risks & what to watch (4)›
Key risks
- Going concern risk — Auditors have expressed substantial doubt about ability to continue as a going concern; cash flow projections indicate inability to meet liabilities within 12 months [sec · filed 2026-05-01].
- Clinical development uncertainty — Company has not completed Phase 3 trials or obtained regulatory approval for any candidate; delays or failures could halt operations [sec · filed 2026-05-01].
- Limited cash runway — Cash of $4.0M as of Dec 31, 2025 may be insufficient to fund planned R&D and operations without additional financing [sec · filed 2026-05-01].
- Regulatory and manufacturing risks — Changes in regulatory requirements or manufacturing/formulation changes could require additional studies and cause delays [sec · filed 2026-05-01].
What to watch
- Initiation and enrollment of clinical trial for intranasal foralumab in secondary progressive multiple sclerosis [sec · filed 2026-05-01].
- Progress of intranasal foralumab program for Type 1 Diabetes and Long COVID [sec · filed 2026-05-01].
- Ability to secure additional financing to fund operations beyond current cash runway [sec · filed 2026-05-01].
- Regulatory updates and any changes to clinical trial timelines or protocols [sec · filed 2026-05-01].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Tiziana Life Sciences Ltd through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tiziana Life Sciences Ltd facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
9.6 months
D/E 1.87
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~31d
3 buys · 0 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
29
Total value held
$847K
| Holder | Shares | Value |
|---|---|---|
| marshall wace, llp | 157,566 | $184K |
| geode capital management, llc | 78,204 | $91K |
| goldman sachs group inc | 75,660 | $89K |
| hsbc holdings plc | 62,437 | $76K |
| morgan stanley | 52,156 | $61K |
| ewa, llc | 45,948 | $54K |
| citadel advisors llc | 35,094 | $41K |
| susquehanna international group, llp | 31,967 | $37K |
| xtx topco ltd | 28,500 | $33K |
| point72 asset management, l.p. | 25,900 | $30K |
Showing top 10 of 29 institutional holders of Tiziana Life Sciences Ltd. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 1.7%
- Days to cover
- 10.0
- Shares short
- 1,456,539
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TLSA short interestFrequently asked questions
What is the AI investment thesis for Tiziana Life Sciences Ltd?
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company developing foralumab, an anti-IL6R monoclonal antibody, primarily via intranasal administration for neurodegenerative and autoimmune indications, with no approved products and recurring operating losses.
What is Tiziana Life Sciences Ltd's next catalyst?
Tiziana Life Sciences Ltd's next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: intranasal foralumab" — expected September 30, 2026.
Who is the CEO of Tiziana Life Sciences Ltd?
Dr. Ivor R. Elrifi Ph.D. is the chief executive officer of Tiziana Life Sciences Ltd (TLSA).
Where is Tiziana Life Sciences Ltd headquartered?
Tiziana Life Sciences Ltd (TLSA) is headquartered in London, United Kingdom.
What therapeutic areas does Tiziana Life Sciences Ltd focus on?
Tiziana Life Sciences Ltd develops therapies across Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.